Yanfeng Liu

Yanfeng Liu is a Research Associate 2 at the Yale School of Medicine, Yale University. His research focuses on tumor modeling and DNA repair mechanisms in cancer cells, with expertise in developing targeted therapies and molecular interventions.

He collaborates with prominent researchers such as Adam Krysztofiak, Franziska Bleichert, and Peter M. Glazer, contributing to advancements in cancer drug development and tumor targeting strategies. His work integrates antibody engineering and molecular biology to inhibit RAD51, a key protein in DNA repair pathways.

Notable contributions include a 2024 publication in Oncotarget detailing next-generation cell-penetrating antibodies for tumor therapy. Liu’s research bridges basic science and translational medicine, aiming to improve cancer treatment efficacy.